ArticleCurrent drug delivery2018
Implementing Central Composite Design for Developing Transdermal Diacerein-Loaded Niosomes: Ex vivo Permeation and In vivo Deposition.
Article in Current drug delivery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Sustained Ocular Delivery of Moxifloxacin-Ufasomes-Laden In Situ Gel for Keratitis Management.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Advances in Drug Delivery Science for Diacerein: Strategies to Enhance Solubility, Bioavailability, and Pharmacokinetic Performance.Pharmaceutics · 2025Review
- Thermoreversible Ionogel for Enhanced Nose-to-brain Delivery of Tetrabenazine Hydrochloride: Optimization by Central Composite Design and In Vitro Ex Vivo Evaluation.AAPS PharmSciTech · 2025Article
- Exploring intracellular anti-mycobacterium activity of lactoferricin-loaded niosomes: proteomics insights into Immunomodulation.Scientific reports · 2025Article
- Stearyl amine tailored spanlastics embedded within tetronicDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2025Article
- Application of quality by design in optimization of nanoformulations: Principle, perspectives and practices.Drug delivery and translational research · 2025Review
- Article
- Article
- Capped flexosomes for prominent anti-inflammatory activity: development, optimization, and ex vivo and in vivo assessments.Drug delivery and translational research · 2024Article
- Article
- Microporation-Mediated Transdermal Delivery of In Situ Gel Incorporating Etodolac-Loaded PLGA Nanoparticles for Management of Rheumatoid Arthritis.Pharmaceutics · 2024Article
- Repurposing celecoxib for colorectal cancer targeting via pH-triggered ultra-elastic nanovesicles: Pronounced efficacy through up-regulation of Wnt/β-catenin pathway in DMH-induced tumorigenesis.International journal of pharmaceutics: X · 2024Article
- Niosome as a promising tool for increasing the effectiveness of anti-inflammatory compounds.EXCLI journal · 2024Review
- Formulation of novel niosomal repaglinide chewable tablets using coprocessed excipients: in vitro characterization, optimization and enhanced hypoglycemic activity in rats.Drug delivery · 2023Article
- Niosomal formulation of mefenamic acid for enhanced cancer targeting; preparation, characterization and biodistribution study using radiolabeling technique.Journal of cancer research and clinical oncology · 2023Article
- Formulation and characterization of lamotrigine nasal insert targeted brain for enhanced epilepsy treatment.Drug delivery · 2023Article
- Applications and recent advances in transdermal drug delivery systems for the treatment of rheumatoid arthritis.Acta pharmaceutica Sinica. B · 2023Review
- Article
- Targeting Colorectal Cancer Cells with Niosomes Systems Loaded with Two Anticancer Drugs Models; Comparative In Vitro and Anticancer Studies.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Effects of Imipenem-containing Niosome nanoparticles against high prevalence methicillin-resistant Staphylococcus Epidermidis biofilm formed.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNiosomes are surfactant-based vesicular nanosystems that proved their efficiency in transdermal delivery by overcoming skin inherent anatomic barrier; startum corneum. Central composite design is an efficient tool for developing and optimizing niosomal formulations using fewer experiments.
objectiveThe objective of this study was to prepare niosomes as a transdermal delivery system of diacerein using film hydration technique, employing central composite design, for avoiding its oral gastrointestinal problems.
methodsThree-level three-factor central composite design was employed for attaining optimal niosomes formulation with the desired characteristics. Three formulation variables were assessed: amount of salt in hydration medium (X1), lipid amount (X2) and number of surfactant parts (X3). DCNloaded niosomes were evaluated for entrapment efficiency percent (Y1), particle size (Y2), polydispersity index (Y3) and zeta potential (Y4). The suggested optimal niosomes were subjected to further characterization and utilized as a nucleus for developing elastic vesicles for comparative ex vivo and in vivo studies.
resultsThe values of the independent variables (X1, X2 and X3) in the optimal niosomes formulation were 0 g, 150 mg and 5 parts, respectively. It showed entrapment efficiency percentage of 95.63%, particle size of 436.65 nm, polydispersity index of 0.47 and zeta potential of -38.80 mV. Results of ex vivo permeation and skin deposition studies showed enhanced skin permeation and retention capacity of the prepared vesicles than drug suspension.
conclusionResults revealed that a transdermal niosomal system was successfully prepared and evaluated using central composite design which will result in delivering diacerein efficiently, avoiding its oral problems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.